News
-
Study Finds Treatment With Metreleptin Improved Diabetes And Lipid Control In Patients With Partial Lipodystrophy
6/4/2011
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy.
This website uses cookies to ensure you get the best experience on our website. Learn more